Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
...Biotech Annual Meeting
- Tides, Las Vegas, USA
- BIO, Vancouver, USA
- microRNA Symposium 2009, Vienna.
- DDD Meeting Japan
4th conference on RNAi, miRNA and siRNA
- XV International Symposium on Atherosclerosis
- 4th Nucleic Acid Chemical Biology (NACB) Symposium...
Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
...s for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index smi
(Swiss Market Index SMI(R)).
About Tufts Medical Center
Tufts Medical Center is an exceptional, not-for-profit, 451-bed academic ...
Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
...g next day functioning."
SUMMARY OF PHASE II smi
ITI-007 is an orally available inves...nnounced interim results showed that patients with smi
treated with ITI-007 experienced dose-dependent in...ght or too early several times a week, symptoms of smi
that are characterized by difficulty staying aslee...
GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd.
...s for significant unmet medical needs. Actelion shares are
traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss
blue-chip index smi
(Swiss Market Index SMI(R))
GeneraMedix Inc. is a privately held pharmaceutical company specializing
in difficult to ...
Cell Therapeutics Receives Additional NASDAQ Notification
and issued additional common shares to smi
shareholders. Marketplace Rule
4350(i)(1)(C) req...d to provide that the Company
shall pay accredited smi
stockholders an immediate substitute "earn-out"
38,186,911 shares of its common stock to smi
stockholders, which is in excess
of 20% of the Com...
Starch Medical Launches New, Bioinert Surgical Hemostats
...led with custom
delivery systems, have been favorably received in a diverse range of surgical
applications in Europe, Asia and Latin America."
is a privately-held medical device company engaged in the design,
manufacture, marketing and licensing of breakthrough, hemostatic solutions.